反应停治疗难治性多发性骨髓瘤6例  

Thalidomide in Therapy of Refractory Multiple Myeloma:Report of 6 Cases

作　　者：陈文新[1] 李新 刘雪梅[1] 包翠华[1] 

机构地区：[1]内蒙古医学院第三附属医院血液科,内蒙古包头014010 [2]呼和浩特市新城区医院,内蒙古呼和浩特010010

出　　处：《内蒙古医学杂志》2003年第6期497-499,共3页Inner Mongolia Medical Journal

摘　　要：目的 :探讨反应停治疗难治性多发性骨髓瘤 (MM )的临床疗效。方法 :对 6例难治疗性多发性骨髓瘤应用反应停治疗后的临床资料进行分析 ,并结合文献复习 ,为该病的治疗提供一条思路。结果 :1例患者达完全缓解 ;1例患者达部分缓解 ;1例进步 ,血清M蛋白减少 35 %、骨痛明显减轻、血沉降低 4 0 %、血红蛋白上升 2 0 g L ;2例无效 ;1例死亡。结论 :反应停对多发性骨髓瘤有较好的疗效 ,不良反应可以耐受且不产生骨髓抑制。抗血管新生是其主要疗效机制。Objective:To inquire the treatment outcome of thalidomide for refractory multiple myiloma.Method:The clinical data of t myeloma treated with thalicomide were reviewed.Result:The were 1 case remitted,1 case remitted partly,1 case effective with decreased serum M protein(35%),relieved ostalgia,lower erythrocyte sedimentation rate (CSR)(40%) and increased hemoglobin(20g/L),2 cases ineffective and 1 case dead.Conclusion:Thalidomide is effective for multiple myeloma with tolerable side-effect and noninhibiton of bone marrow.Antivascularization is its main mechanism.

关 键 词：难治性多发性骨髓瘤 反应停 药物治疗 抗血管新生 疗效 

分 类 号：R733.3[医药卫生—肿瘤] R979.1[医药卫生—临床医学]